The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform
C. Conrad - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in Acrodermatitis Continua of Hallopeau
Journal of the European Academy of Dermatology and Venereology, 2020Co-Authors: B. Husson, C. Barbe, S. Hegazy, J. Seneschal, F. Aubin, E. Mahé, D. Jullien, E. Sbidian, M. D'incan, C. ConradAbstract:Palmoplantar pustulosis (PPP) and Acrodermatitis Continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce.
-
efficacy and safety of tnf blockers and of ustekinumab in palmoplantar pustulosis and in Acrodermatitis Continua of hallopeau
Journal of The European Academy of Dermatology and Venereology, 2020Co-Authors: B. Husson, C. Barbe, S. Hegazy, J. Seneschal, F. Aubin, E. Mahé, D. Jullien, E. Sbidian, M Dincan, C. ConradAbstract:BACKGROUND Palmoplantar pustulosis (PPP) and Acrodermatitis Continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce. OBJECTIVES To evaluate the real-life efficacy of tumour necrosis factor blockers and ustekinumab in PPP and in ACH. METHODS A multicentre retrospective descriptive study was conducted in 19 dermatology departments, including all patients with PPP or ACH seen from 2014 to 2016 who received one of the studied biologics. The data were collected by a standardized document. Factors associated with complete clearance (CC) were analysed by multivariate analysis, estimating odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS Among 92 patients included, 50 received adalimumab, 44 ustekinumab, 36 etanercept and 31 infliximab. Improvement and CC were observed in 83.9% and 20.0% patients receiving infliximab, 75.0% and 38.6% ustekinumab, 57.1% and 20.0% etanercept and 60.4% and 29.2% adalimumab. We found no significant difference in CC rates or duration of treatment among the biological treatments (P = 0.18 and P = 0.10, respectively). On multivariate analysis, CC with etanercept was associated with the ACH form and not smoking [OR = 9.5 (95% CI 1.1-82.7), P = 0.04 and 0.1 (0.01-0.9), P = 0.04]; with ustekinumab, male sex and absence of obesity [6.0 (1.3-28.6), P = 0.02 and 4.7 (1.0-22.7), P = 0.05]; with adalimumab, the ACH form [11.9 (2.7-52.3), P = 0.001]; and with infliximab, obesity [5.6 (1.1-29.4), P = 0.04]. CONCLUSIONS We found no difference in efficacy between TNF blockers and ustekinumab and among the three different TNF blockers in real life for PPP or ACH, which reveals the heterogeneity of clinical response to biologics in pustular psoriasis as compared with plaque psoriasis.
Henry K. Wong - One of the best experts on this subject based on the ideXlab platform.
-
Acrodermatitis Continua of Hallopeau Successfully Treated with Adalimumab
The Journal of clinical and aesthetic dermatology, 2012Co-Authors: Jennifer Sopkovich, Georgann Anetakis Poulos, Henry K. WongAbstract:Acrodermatitis Continua of Hallopeau, first described by Hallopeau in 1890, is an uncommon variant of pustular psoriasis. Acrodermatitis Continua of Hallopeau presents as sterile pustules on the hands and feet. It has a relapsing course. Although Acrodermatitis Continua of Hallopeau is a pustular psoriasis variant, the condition is not easily treated with antipsoriatic medications. In the following case, the authors report a case of Acrodermatitis Continua of Hallopeau successfully treated with adalimumab. In addition, the cases of Acrodermatitis Continua of Hallopeau treated with tumor necrosis-alpha inhibitors are summarized.
B. Husson - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in Acrodermatitis Continua of Hallopeau
Journal of the European Academy of Dermatology and Venereology, 2020Co-Authors: B. Husson, C. Barbe, S. Hegazy, J. Seneschal, F. Aubin, E. Mahé, D. Jullien, E. Sbidian, M. D'incan, C. ConradAbstract:Palmoplantar pustulosis (PPP) and Acrodermatitis Continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce.
-
efficacy and safety of tnf blockers and of ustekinumab in palmoplantar pustulosis and in Acrodermatitis Continua of hallopeau
Journal of The European Academy of Dermatology and Venereology, 2020Co-Authors: B. Husson, C. Barbe, S. Hegazy, J. Seneschal, F. Aubin, E. Mahé, D. Jullien, E. Sbidian, M Dincan, C. ConradAbstract:BACKGROUND Palmoplantar pustulosis (PPP) and Acrodermatitis Continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce. OBJECTIVES To evaluate the real-life efficacy of tumour necrosis factor blockers and ustekinumab in PPP and in ACH. METHODS A multicentre retrospective descriptive study was conducted in 19 dermatology departments, including all patients with PPP or ACH seen from 2014 to 2016 who received one of the studied biologics. The data were collected by a standardized document. Factors associated with complete clearance (CC) were analysed by multivariate analysis, estimating odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS Among 92 patients included, 50 received adalimumab, 44 ustekinumab, 36 etanercept and 31 infliximab. Improvement and CC were observed in 83.9% and 20.0% patients receiving infliximab, 75.0% and 38.6% ustekinumab, 57.1% and 20.0% etanercept and 60.4% and 29.2% adalimumab. We found no significant difference in CC rates or duration of treatment among the biological treatments (P = 0.18 and P = 0.10, respectively). On multivariate analysis, CC with etanercept was associated with the ACH form and not smoking [OR = 9.5 (95% CI 1.1-82.7), P = 0.04 and 0.1 (0.01-0.9), P = 0.04]; with ustekinumab, male sex and absence of obesity [6.0 (1.3-28.6), P = 0.02 and 4.7 (1.0-22.7), P = 0.05]; with adalimumab, the ACH form [11.9 (2.7-52.3), P = 0.001]; and with infliximab, obesity [5.6 (1.1-29.4), P = 0.04]. CONCLUSIONS We found no difference in efficacy between TNF blockers and ustekinumab and among the three different TNF blockers in real life for PPP or ACH, which reveals the heterogeneity of clinical response to biologics in pustular psoriasis as compared with plaque psoriasis.
Natalija Novak - One of the best experts on this subject based on the ideXlab platform.
-
successful treatment of Acrodermatitis Continua suppurativa with topical tacrolimus 0 1 ointment
British Journal of Dermatology, 2004Co-Authors: Dagmar Wilsmanntheis, Tobias Hagemann, H Dederer, Joerg Wenzel, Thomas Bieber, Natalija NovakAbstract:Acrodermatitis Continua suppurativa of Hallopeau (ACS) is a rare pustular variant of psoriasis in which numerous treatment modalities have been used without any consistent long-term effect. We report for the first time two patients with ACS which was successfully treated with topical tacrolimus 0.1% ointment. Our observations raise hopes that this new treatment strategy for ACS may constitute a novel effective therapeutic option for this recalcitrant condition.
D. Jullien - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in Acrodermatitis Continua of Hallopeau
Journal of the European Academy of Dermatology and Venereology, 2020Co-Authors: B. Husson, C. Barbe, S. Hegazy, J. Seneschal, F. Aubin, E. Mahé, D. Jullien, E. Sbidian, M. D'incan, C. ConradAbstract:Palmoplantar pustulosis (PPP) and Acrodermatitis Continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce.
-
efficacy and safety of tnf blockers and of ustekinumab in palmoplantar pustulosis and in Acrodermatitis Continua of hallopeau
Journal of The European Academy of Dermatology and Venereology, 2020Co-Authors: B. Husson, C. Barbe, S. Hegazy, J. Seneschal, F. Aubin, E. Mahé, D. Jullien, E. Sbidian, M Dincan, C. ConradAbstract:BACKGROUND Palmoplantar pustulosis (PPP) and Acrodermatitis Continua of Hallopeau (ACH) are rare variants of psoriasis. Knowledge of the efficacy of biologics is scarce. OBJECTIVES To evaluate the real-life efficacy of tumour necrosis factor blockers and ustekinumab in PPP and in ACH. METHODS A multicentre retrospective descriptive study was conducted in 19 dermatology departments, including all patients with PPP or ACH seen from 2014 to 2016 who received one of the studied biologics. The data were collected by a standardized document. Factors associated with complete clearance (CC) were analysed by multivariate analysis, estimating odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS Among 92 patients included, 50 received adalimumab, 44 ustekinumab, 36 etanercept and 31 infliximab. Improvement and CC were observed in 83.9% and 20.0% patients receiving infliximab, 75.0% and 38.6% ustekinumab, 57.1% and 20.0% etanercept and 60.4% and 29.2% adalimumab. We found no significant difference in CC rates or duration of treatment among the biological treatments (P = 0.18 and P = 0.10, respectively). On multivariate analysis, CC with etanercept was associated with the ACH form and not smoking [OR = 9.5 (95% CI 1.1-82.7), P = 0.04 and 0.1 (0.01-0.9), P = 0.04]; with ustekinumab, male sex and absence of obesity [6.0 (1.3-28.6), P = 0.02 and 4.7 (1.0-22.7), P = 0.05]; with adalimumab, the ACH form [11.9 (2.7-52.3), P = 0.001]; and with infliximab, obesity [5.6 (1.1-29.4), P = 0.04]. CONCLUSIONS We found no difference in efficacy between TNF blockers and ustekinumab and among the three different TNF blockers in real life for PPP or ACH, which reveals the heterogeneity of clinical response to biologics in pustular psoriasis as compared with plaque psoriasis.
-
Acrodermatitis Continua of hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra
Dermatology, 2015Co-Authors: Jordane Saunier, D. Jullien, S Debarbieux, Lorna Garnier, S Dalle, L ThomasAbstract:Acrodermatitis Continua of Hallopeau (ACH) is a rare form of chronic acral pustular eruption. Considered to be a variant of pustular psoriasis, it is a refractory condition that may not respond to conventional treatments. We report herein the case of a 53-year-old patient whose ACH was refractory to all conventional systemic treatment modalities and to anti-tumour necrosis factor. Because he had increased plasma levels of interleukin (IL)-1β, he received anakinra for 7 weeks, without further improvement however. Achievement of complete response was obtained with ustekinumab 90 mg s.c. every 12 weeks combined with acitretin; the plasma level of IL-1β concomitantly returned to normal. This case report is associated with a review on recent data on ACH treatment with biological agents, including anakinra and ustekinumab.